CLRB Fundamental Analysis - CELLECTAR BIOSCIENCES INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to CLRB. CLRB was compared to 558 industry peers in the Biotechnology industry. While CLRB seems to be doing ok healthwise, there are quite some concerns on its profitability. CLRB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

CLRB had negative earnings in the past year.

In the past year CLRB has reported a negative cash flow from operations.

In the past 5 years CLRB always reported negative net income.

In the past 5 years CLRB always reported negative operating cash flow.

1.2 Ratios

CLRB has a worse Return On Assets (-152.99%) than 85.66% of its industry peers.

CLRB has a Return On Equity of -254.72%. This is in the lower half of the industry: CLRB underperforms 70.61% of its industry peers.

		Industry Rank	Sector Rank
ROA	-152.99%
ROE	-254.72%
ROIC	N/A

ROA(3y)-220.55%

ROA(5y)-150.45%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLRB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CLRB has more shares outstanding than it did 1 year ago.

CLRB has more shares outstanding than it did 5 years ago.

CLRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CLRB has an Altman-Z score of -29.74. This is a bad value and indicates that CLRB is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -29.74, CLRB is doing worse than 89.96% of the companies in the same industry.

There is no outstanding debt for CLRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-29.74

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.47 indicates that CLRB has no problem at all paying its short term obligations.

CLRB has a worse Current ratio (2.47) than 70.25% of its industry peers.

CLRB has a Quick Ratio of 2.47. This indicates that CLRB is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of CLRB (2.47) is worse than 68.46% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.47
Quick Ratio	2.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.35% over the past year.

EPS 1Y (TTM)78.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%81.08%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.15% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y51.63%

EPS Next 2Y21.44%

EPS Next 3Y13.47%

EPS Next 5Y13.15%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CLRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CLRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CLRB's earnings are expected to grow with 13.47% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y21.44%

EPS Next 3Y13.47%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CLRB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CELLECTAR BIOSCIENCES INC

NASDAQ:CLRB (6/23/2025, 10:38:28 AM)

0.2881

0 (-0.66%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-13 2025-05-13/bmo

Earnings (Next)08-11 2025-08-11/bmo

Inst Owners12.42%

Inst Owner Change5.04%

Ins Owners1.48%

Ins Owner Change0%

Market Cap13.28M

Analysts80

Price Target3.06 (962.13%)

Short Float %3.21%

Short Ratio0.1

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)49.64%

Min EPS beat(2)15.96%

Max EPS beat(2)83.31%

EPS beat(4)3

Avg EPS beat(4)46.37%

Min EPS beat(4)-5.28%

Max EPS beat(4)91.47%

EPS beat(8)3

Avg EPS beat(8)10.55%

EPS beat(12)5

Avg EPS beat(12)10.78%

EPS beat(16)9

Avg EPS beat(16)10.13%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-47.06%

PT rev (3m)-47.06%

EPS NQ rev (1m)0%

EPS NQ rev (3m)20.37%

EPS NY rev (1m)2.78%

EPS NY rev (3m)14.53%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)-100%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.38
P/tB	1.38
EV/EBITDA	N/A

EPS(TTM)-0.63

EYN/A

EPS(NY)-0.65

Fwd EYN/A

FCF(TTM)-0.95

FCFYN/A

OCF(TTM)-0.95

OCFYN/A

SpS0

BVpS0.21

TBVpS0.21

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-152.99%
ROE	-254.72%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-220.55%

ROA(5y)-150.45%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.47
Quick Ratio	2.47
Altman-Z	-29.74

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)212.71%

Cap/Depr(5y)154.86%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)78.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%81.08%

EPS Next Y51.63%

EPS Next 2Y21.44%

EPS Next 3Y13.47%

EPS Next 5Y13.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-9.3%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-58.52%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-59.37%

OCF growth 3YN/A

OCF growth 5YN/A

CELLECTAR BIOSCIENCES INC (CLRB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens